دورية أكاديمية
أعرض في EDS

NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab.

التفاصيل البيبلوغرافية
العنوان: NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab.
المؤلفون: Signoriello E; Second Division of Neurology, University of Campania Luigi Vanvitelli - Naples, Italy., Signori A; Department of Health Sciences, Section of Biostatistics, University of Genoa, Genoa, Italy., Lus G; Second Division of Neurology, University of Campania Luigi Vanvitelli - Naples, Italy., Romano G; Second Division of Neurology, University of Campania Luigi Vanvitelli - Naples, Italy., Marfia GA; Multiple Sclerosis Clinical and Research Unit, Department of System Medicine, Tor Vergata University, Rome, Italy., Landi D; Multiple Sclerosis Clinical and Research Unit, Department of System Medicine, Tor Vergata University, Rome, Italy., Napoli F; Multiple Sclerosis Clinical and Research Unit, Department of System Medicine, Tor Vergata University, Rome, Italy., D' Amico E; Department of Medical and Surgical Sciences, University of Foggia, Italy., Zanghí A; Department of Medical and Surgical Sciences, University of Foggia, Italy., Di Filippo PS; Department of Medical and Surgical Sciences, University of Foggia, Italy., Caliendo D; Department of Neuroscience, Reproductive Science and Odontostomatology, Federico II University of Naples, Naples, Italy., Carotenuto A; Department of Neuroscience, Reproductive Science and Odontostomatology, Federico II University of Naples, Naples, Italy., Spiezia AL; Department of Neuroscience, Reproductive Science and Odontostomatology, Federico II University of Naples, Naples, Italy., Fantozzi R; IRCCS Neuromed, 86077 Pozzilli, Italy., Centonze D; IRCCS Neuromed, 86077 Pozzilli, Italy; Department of System Medicine, Tor Vergata University, 00133 Rome, Italy., Lucchini M; Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy; Università Cattolica del Sacro Cuore, CERSM, Roma, Italy., Mirabella M; Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy; Università Cattolica del Sacro Cuore, CERSM, Roma, Italy., Cocco E; Multiple Sclerosis Centre, ASL Cagliari, Cagliari, Italy; Dpt of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy., Frau J; Multiple Sclerosis Centre, ASL Cagliari, Cagliari, Italy., Maniscalco GT; MS and Neuroimmunology Center, A Cardarelli Hospital,Naples, Italy., Di Battista ME; MS and Neuroimmunology Center, A Cardarelli Hospital,Naples, Italy., Foschi M; Department of Neuroscience, Multiple Sclerosis Center - Neurology Unit, S.Mariadelle Croci Hospital, AUSL Romagna, Ravenna, Italy; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy., Surcinelli A; Department of Neuroscience, Multiple Sclerosis Center - Neurology Unit, S.Mariadelle Croci Hospital, AUSL Romagna, Ravenna, Italy., Bonavita S; Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, I Clinic of Neurology, University of Campania 'Luigi Vanvitelli,' Naples, Italy., Abbadessa G; Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, I Clinic of Neurology, University of Campania 'Luigi Vanvitelli,' Naples, Italy., Pasquali L; Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy., Di Gregorio M; Neurology Unit, University Hospital 'San Giovanni di Dio e Ruggi d'Aragona', Largo Città di Ippocrate, 84100, Salerno, Italy., Ferrò MT; Neuroimmunology and Multiple Sclerosis Center, A.S.S.T. of Crema, Italy., Sormani MP; Department of Health Sciences, Section of Biostatistics, University of Genoa, Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Schiavetti I; Department of Health Sciences, Section of Biostatistics, University of Genoa, Genoa, Italy. Electronic address: irene.schiavetti@unige.it.
مؤلفون مشاركون: ON focus study group
المصدر: Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2024 Jul; Vol. 87, pp. 105594. Date of Electronic Publication: 2024 Apr 06.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier B. V Country of Publication: Netherlands NLM ID: 101580247 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2211-0356 (Electronic) Linking ISSN: 22110348 NLM ISO Abbreviation: Mult Scler Relat Disord Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Amsterdam] : Elsevier B. V.
مواضيع طبية MeSH: Natalizumab*/therapeutic use , Natalizumab*/administration & dosage , Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/pharmacology , Multiple Sclerosis, Relapsing-Remitting*/drug therapy , Immunologic Factors*/administration & dosage , Immunologic Factors*/pharmacology, Humans ; Female ; Male ; Adult ; Retrospective Studies ; Young Adult ; Disease Progression
مستخلص: Background: in the early stages of Multiple Sclerosis (MS), initiating high-efficacy disease-modifying therapy (HE DMTs) may represent an optimal strategy for delaying neurological damage and long-term disease progression, especially in highly active MS patients (HAMS). Natalizumab (NAT) and Ocrelizumab (OCR) are recognized as HE DMTs with significant anti-inflammatory effects. This study investigates NEDA-3 achievement in treatment-naïve HAMS patients receiving NAT or OCR over three years.
Methods: we retrospectively enrolled treatment-naïve HAMS patients undergoing NAT or OCR, collecting demographic, clinical, and instrumental data before and after treatment initiation to compare with propensity score analysis disease activity, time to disability worsening, and NEDA-3 achievement.
Results: we recruited 281 HAMS patients with a mean age of 32.7 years (SD 10.33), treated with NAT (157) or OCR (124). After three years, the Kaplan-Meier probability of achieving NEDA-3 was 66.0 % (95 % CI: 57.3 % - 76.0 %) with OCR and 68.2 % (95 % CI: 59.9 % - 77.7 %) with NAT without significant differences between the two groups (p = 0.27) DISCUSSION AND CONCLUSION: starting HE DMT with monoclonal antibodies for HAMS could achieve NEDA-3 in a high percentage of patients without differences between NAT or OCR.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Irene Schiavetti reports a relationship with Roche, Biogen, Horizon, Novartis, Hoya, Hippocrates Research, D.M.G Italia, Eyepharma, DreamsLab that includes: consulting or advisory. Livia Pasquali reports a relationship with Alexion, Biogen, Sanofi, Merck, Novartis, Roche that includes: consulting or advisory and travel reimbursement. Elisabetta Signoriello reports a relationship with Almirall, Biogen, Genzyme, Novartis, Teva that includes: board membership and travel reimbursement. Maria Pia Sormani reports a relationship with Biogen Idec, Merck Serono, Teva, Genzyme, Roche, Novartis, GeNeuro, Medday that includes: consulting or advisory. Jessica Frau reports a relationship with Biogen, Bristol, Novartis, Genzyme, Merck, Teva, Alexion that includes: board membership, consulting or advisory, and speaking and lecture fees. Daniele Caliendo reports a relationship with Merck that includes: funding grants. Alessio Signori reports a relationship with Roche, Horizon, Novartis that includes: speaking and lecture fees. Andrea Surcinelli reports a relationship with Roche, Merck, Biogen, Sanofi, Novartis that includes: travel reimbursement. Simona Bonavita reports a relationship with Novartis, Merck-Serono, Alexion, BMS, Biogen, Roche, Janssen-Cilag, Horizon that includes: speaking and lecture fees and travel reimbursement. Roberta Fantozzi reports a relationship with Novartis, Roche, Merck Serono, Bristol-Myers Squibb that includes: board membership and consulting or advisory. Antonio Carotenuto reports a relationship with Almirall, ECTRIMS- MAGNIMS, Biogen, Roche, Sanofi-Genzyme, Merck, Ipsen, Novartis that includes: funding grants. Doriana Landi reports a relationship with Biogen, Merck Serono, Teva, Bristol Myers Squibb, Mylan, Novartis, Roche, Horizon, Alexion, Sanofi-Genzyme, Novartis, Bayer-Schering that includes: speaking and lecture fees and travel reimbursement. Giacomo Lus reports a relationship with Biogen Idec, Merck Serono, Novartis, Sanofi- Aventis Pharmaceuticals, Teva neuroscience that includes: funding grants. Eleonora Cocco reports a relationship with Biogen, Merck, Novartis, Roche, Genzyme that includes: consulting or advisory and funding grants. Matteo Lucchini reports a relationship with Biogen, Merck Serono, Novartis, Roche, Sanofi-Genzyme, Almirall, Horizon, Bayer that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Girolama Alessandra Marfia reports a relationship with Almirall, Bayer-Schering, Biogen, Sanofi Genzyme, Merck Serono, Novartis, Teva, Mylan, Bristol Mayers Squibb, Roche, Biogen that includes: consulting or advisory, funding grants, speaking and lecture fees, and travel reimbursement. Matteo Foschi reports a relationship with Merck, Biogen, Sanofi, Roche, Novartis that includes: consulting or advisory and travel reimbursement. Massimiliano Mirabella reports a relationship with Bayer Schering, Biogen, Sanofi-Genzyme, Merck, Novartis, Teva, Mylan, Almirall, CSL Behring, Roche, Ultragenix that includes: board membership, consulting or advisory, speaking and lecture fees, and travel reimbursement. Diego Centonze reports a relationship with Almirall, Bayer Schering, Biogen, GW Pharmaceuticals, Merck Serono, Novartis, Roche, Sanofi-Genzyme, Protagon, Sandoz, Bristol-Myers Squibb, Alexion, Mitsubishi, Teva, Celgene that includes: board membership, funding grants, and non-financial support. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
فهرسة مساهمة: Keywords: High-efficacy disease-modifying therapy (HE DMTs); Highly active MS patients (HAMS); Multiple sclerosis; NEDA-3; Natalizumab; Ocrelizumab
المشرفين على المادة: 0 (Natalizumab)
A10SJL62JY (ocrelizumab)
0 (Antibodies, Monoclonal, Humanized)
0 (Immunologic Factors)
تواريخ الأحداث: Date Created: 20240508 Date Completed: 20240616 Latest Revision: 20240616
رمز التحديث: 20240617
DOI: 10.1016/j.msard.2024.105594
PMID: 38718748
قاعدة البيانات: MEDLINE
الوصف
تدمد:2211-0356
DOI:10.1016/j.msard.2024.105594